Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide.
Vincenza ConteducaChiara CasadeiEmanuela ScarpiNicole BrighiGiuseppe SchepisiCristian LolliGiorgia GurioliIlaria TomaGiulia PotiAlberto FarolfiUgo De GiorgiPublished in: Cancers (2022)
Elevated ctDNA levels and AR gain are negatively and independently correlated with PSA kinetics in mCRPC men treated with abiraterone or enzalutamide.